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PRELIMINARY AND SHORT REPORTS
ARTANE IN THE TREATMENT OF MORPHEA AND SCLERODERMA*
A Preliminary Report
HARRY M. ROBINSON, Sa., M.D.
The treatment of Morphea has, until the use of the drug reported here, resulted in
failure, in my experience. Many drugs, including the antibiotics, proved valueless. ACTH
and Cortisone have not given more than temporary improvement (1, 2). In a search for a
more satisfactory treatment for Morphea, a drug was found, which had hitherto been used
in Parkinsonism.
THE DRUG AND DOSAGE
This drug, known commercially as Artanct is one of the piperidyl group with the for-
mula: 3-(N-piperidyl)-1-phenyl-1-cyclohexyl-1-propanol HC1. In rats, the LD1 was found
to be 30mg. per kg. In dogs, 50 mg. per kg. of Artane produced mydriasis; this is approxi-
mately SO times the highest dose recommended for human use.
It is emphasized by Schwab and Tillman (3) that the effective dose of this drug varies
and, although 0.5 mg. per kg. is an accepted therapeutic dose, it should not be used in-
discriminately. In this report, some (ages 15 to 30) could take 2 mg. four times a day with-
out reaction, u-bile those over 50 could tolerate only 2 to 4 mg. per day. In this series it was
found that the best plan was to give increasing doses, starting with one to two milligrams
daily.
PHARMACOLOGY
Artane is primarily an antispasmodic, but also has the following side actions: 1. Cardio-
vagal inhibition; 2. Excitation of the central nervous system; 3. Mydriasis; 4. Anti-sial-
ogogue; 5. Hyperglycemia.
REACTIONS
Mouth dryness (note anti-sialogogue action), dizziness and feeling "drunk" (from nerv-
ous system excitation), "fluttering around the heart," possibly due to cardio-vagal
inhibition. As it causes hyperglycemia, one should exclude diabetic patients, or those so
inclined.
CA5E5 AND EE5ULT5
This report deals only with those patients whose diagnosis (except those with kraurosis
vulvae) have been verified by biopsy, and who have continued treatment over varying
periods up to 16 months. A few patients (three) who had shown improvement, stopped
treatment because of dizziness, vague "fluttering" around the heart, and mouth dryness.
CGSc 1. J. S., married, white male, age 57. Duration: 4 years. Condition began on fingers,
•extended to hands, then attacked the neck and cheeks, constricting the mouth; later the
upper and lower extremities, feet and pectoral muscles were involved. has been under
Artane treatment since February, 1951 with marked improvement in three months. Can
sometimes take 6mg., but best tolerates 2mg. a day. Improvement: 75% (least on hands).
Diagnosis: Acrosclerosis type of scleroderma.
* From the Department of Dermatology, School of Medicine, University of Maryland.
Received for publication June 5, 1952.
t Supplied through the kindness of Dr. Stanton M. Hardy, for the Lederle Laboratories
Division.
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Case 2. II. W. S., married, white female, age 30. Condition began 234 years ago with
lesions extending from the right buttocks to the ankle; then developed plaques on the
abdomen, breasts and chest. The largest area was 8 cm. in diameter. Began Artane treat-
ment January, 1951. Has taken 6 to 8 mg. daily. Almost all lesions had regressed in three
months, leaving hyperpigmentation but no thickening or hardness. Improvement: 95%.
Still under treatment. Only three small areas (1 to 2 cm.) show any shinyness or ivory
color. Diagnosis: Morphea type of scleroderma.
Case 3. N. B., married, white female, age 55. Condition began 234 years ago with large,
hard, raised, ivory colored plaques involving the abdomen, breasts and back. Began Artane
February, 1951. Occasional dizziness on 6mg. daily, and dose was reduced to 4mg. in May,
1952. Almost all infiltration had regressed in 234 months. Under emotional stress, lesions
became hyperemic, but not hard. Improvement: clinically 100%. Diagnosis: Morphea type
of sclcroderma.
Case 4. J. F., married, white female, age 23. Condition began 534 years ago as one hard,
ivory colored plaque, 2 x 5 cm. on the areola of the left breast. Began Artane treatment
June, 1951. After 11 months, lapsed treatment for 334 months, then resumed it. Takes 8mg.
a day. Shinyness has disappeared, lesion much softer, and one-half the original size. Diag-
nosis: Morphea type of scleroderma.
CaseS. D. Z., married, white male, age 25. Disease began 1 year ago with small, hard,
white areas which varied from 2 cm. in diameter, to 3 x 6 cm. All except two lesions are
atrophic and have a purplish appearance, like a bruise. The two exceptions are silvery
white, raised and hard. Began Artane February, 1951; 234 months later there was no hard-
ness or elcvation. One small plaque has entirely regressed, clinically, and the larger plaque
is "breaking up" and showing normal skin color. Improvement: 70%. No new lesions since
beginning treatment. Diagnosis: Morphea type of sclcroderma.
Case 6. L. J. B.,t single, white female, age 15. Disease has been present five years. Began
as a hard, white area on the forchead and extended into the scalp for 12 cm. Then a lesion
appeared on the left side of the chin, under the left eye, and both sides of the nose. All arcas
had become atrophic. Began Artane one month ago. Can take 8mg. daily without reaction.
Beginning improvement. Diagnosis: Coup-dc-sabre type of sclcrodcrma.
Case 7. I. M.,3 married, white female, age 46. Duration: 4 years, with morphea lesions on
apposiag surfaces of the labia majora. Began Artaae two weeks ago. Improvement: sub-
jectively and objectively, 75%. Impression: Morphca with kraurosis vulvac.
Case 8. II. W., married, white woman, age 54, referred with clinical diagnosis of kraurosis
vulvae by a competent gynecologist, for advice as to vulvectomy. The vulva had a reddish,
sclerotic, glazed appearance with edema, and on the inner surface of the labia, white, hard
spots, 3 to 5 mm. in diameter each. Started on Artane March 31, 1952. On May 5, all white
spots, redness, edema and glazed appearance had disappeared. 11cr gynecologist told her
she was well, and did not require a vulvectomy. An atrophic surface remained. Improve-
ment: subjectively 100%, objectively, 95%. Impression: Morphea guttata with kraurosis
vulvae.
suvvAav AND CoNcLusIoNs
1. All previous treatment for morphea having failed, other treatment has been sought,
and an anti-spasmodic drug, Artane, has been investigated in morphea and sclaroderma. It
* Case referred by Dr. Francis A. Ellis.
3 Case referred by Dr. Ilarry M. Robinson, Jr.
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is felt that the cardio-vagal inhibitory and anti-spasmodic effects are responsible for the
results obtained.
2. This drug must he given in small doses to avoid frightening, hut, in this small series,
benign reactions.
3. The younger the lesion, the more quickly it responds to treatment.
4. Early morphea associated with kraurosis vulvae responds in shorter time than sclero-
dermas of longer duration.
5. The histopathological picture has not changed appreciably yet) in spite of clinical
improvement.
6. It is hoped that if these results are verified by others, new avenues may be opened
toward a more definite etiology.
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